TIRCON: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)
Phase of Trial: Phase III
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Deferiprone (Primary)
- Indications Pantothenate kinase-associated neurodegeneration
- Focus Registrational; Therapeutic Use
- Acronyms TIRCON
- Sponsors ApoPharma
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Nov 2016 This trial has been completed in Germany (end date:2016-10-21), according to European Clinical Trials Database record.
- 30 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov